Vilde D Haakensen
@vilded
Followers
197
Following
399
Media
21
Statuses
229
Thoracic oncologist and cancer researcher. Teacher of Acem meditation.
Oslo, Norway
Joined March 2009
Another failure for TIGIT as a target as Skyscraper-03 failed to improve survival for pts undergoing CRT for NSCLC when adding anti-TIGIT to PD-L1-inh.
0
0
1
So far, neoadjuvant chemo-IO is given to pts with respectable disease. But could it also be used for downstaging of borderline respectable disease? That is explored in the MDT-bridge trial. Borderline respectable pts where given 2 cycles before new MDT. 71% got surgery.
0
0
1
Tarlatamab continues to impress. In the Dellphi 303 study where Tarlatamab was given with chemo and PD-L1 inhibitor from the start in 1L. 👉12m OS 81% NB! Phase 1b non-randomised, n=96. This promises a new era for our patients!
1
0
2
Zongertinib and sevabertinib are both promising as HER2-TKIs also in 1L. Presented by Sanjay Popat and Xiuning Le. Awaiting results from phase 3 trials.
0
0
1
No survival benefit of adding atezolizumab to CRT for SCLC-LD in the ACHIlES-Trial presented by Bjørn Henning Grønberg at #ASCO25 today. The discussant stressed the exceptionally good outcome in the control arm, the benefit of PCI and the possibly of twice-daily fractionation.
0
0
1
Prognostic value of FDG-PET before treatment with ipi/nivo +/- the UV1 vaccine for pts with mesothelioma. Congrats Solfrid Thunold!
link.springer.com
European Journal of Nuclear Medicine and Molecular Imaging - The introduction of immunotherapy in pleural mesothelioma (PM) has highlighted the need for effective outcome predictors. This study...
0
1
2
Åslaug Helland oppdaterer om IMPRESS-Norway på ASCO #ASCO24
https://t.co/z6hmZfcMTI
dagensmedisin.no
Siden oppstarten i 2021 er 1752 pasienter blitt inkludert i Impress. Det er fortsatt langt unna målet til Åslaug Helland.
0
4
11
OUS får nøkkelrolle i stort europeisk kreftsamarbeid. https://t.co/g1IXHNNp73
@KaasaStein
oslo-universitetssykehus.no
OUS er sentral i to store europeiske prosjekter; EUnetCCC og JANE2. OUS sin bit av kaka er henholdsvis 110 og 30 millioner kroner.
1
3
14
Survival-data from the NIPU-trial randomising pts with pleural mesotheliom to double ICI alone or with telomerase vaccine UV1.
0
1
19
Veldig gøy med positive resultater for NIPU-studien! Dataene presenteres på ESMO. @HellandAslaug @Ultimovacs
0
0
10
Ultimovacs kunngjorde tirsdag kveld at det har vært en signifikant og klinisk relevant økning i totaloverlevelse blant pasienter med brysthinnekreft som mottok kreftvaksinen UV1 i fase 2-studien NIPU. https://t.co/qoaNgpawOm
healthtalk.no
Ultimovacs kunngjorde tirsdag kveld at det har vært en signifikant og klinisk relevant økning i totaloverlevelse blant pasienter med brysthinnekreft som mottok kreftvaksinen UV1 i fase 2-studien NIPU.
0
3
17
Nesten alene verdt Aftenposten-abonnementet. Ære være norsk presse!
0
1
13
Åslaug Helland fikk i dag overrakt Kong Olav´s kreftforskningspris av Kong Harald i Universitetets Aula. Gratulerer, Åslaug - vel fortjent! @HellandAslaug
0
3
17
Today, @HellandAslaug received the prestigious King Olav V's Cancer Research Prize from King Harald V of Norway. A well-deserved recognition, congratulations!
0
1
15
Alkohol har en negativ effekt på hele 200 sykdommer. Gitt det er det en naturlig konsekvens at kostrådene, som er der for å ivareta hensyn til helsen, anbefaler avhold. https://t.co/hY7YnNHrnI
vg.no
I arbeidet med de nye nordiske kostholdsrådene, har utkastet til råd om alkoholbruk blitt skjerpet betraktelig. Nå kan rådet bli at totalavhold er det beste.
30
13
85
Great scientific input and lots of inspiration from excellent researchers: @MariamJHanjani @DouglasHanahan @Aslan_Tasdogan #CancerCrosslinks @OsloCancer
0
1
7
#Kreftforeningen setter søkelyset på kliniske studier og klinisk kreftforskning. Bra! #AnnRita_H Hege Edvardsen m flere bidrar
0
0
5
Marianne van der Wel fra HOD viser tiltak for ytterligere økning i kliniske studier. #Kreftforeningen #AnnRita_H
1
1
3
The shout-out and congrats 🙌 go to @HellandAslaug and @vilded at @Oslounivsykehus and the team leading the NIPU ph2 study in malignant #mesothelioma, and everyone who is contributing! Ultimovacs is proud and grateful to support the study. Data readout expected during H1 23.
Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma
0
3
18